Sinusitis, commonly known as a sinus infection, occurs when the nasal cavities become infected, swollen, and inflamed. While ...
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
a chronic condition for which new and effective treatments are needed. Patients now have a non-surgical option available to them and an alternative to repeated exposure to oral corticosteroids.” It is ...
They typically result from seasonal allergies or a bacterial infection requiring medical treatment ... nasal passages. These tests can reveal mucus blockages and any abnormal structures, such as ...
It is caused by physical blockages in the nasal passages, such as a deviated septum, nasal polyps, or enlarged adenoids. • The sounds /m/, /n/, and /ng/ sound like /b/, /d/, and /g/. Mixed rhinolalia: ...
CHENNAI: It’s surprising how many of us struggle with breathing — even though it is the most natural thing to do. But ...
This treatment involves ... may be prescribed to reduce nasal inflammation, mucus production, and congestion, such as: Your healthcare provider will instruct you when and how often to use your ...
Treating allergies can reduce snoring by opening up the nasal passages. Treatments include nasal steroid sprays and non-sedating antihistamines. 2. Surgery for Structural Issues Specific structural ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living ... and misuse. "Treatment-resistant depression can be very complicated, especially ...